Announcements Trials

Browse Landscape

Phase

Status

Recruiting 3 Unknown 2 Completed 2 Terminated 1 Not yet recruiting 1

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 474 Carcinoma, Non-Small-Cell Lung 449 Breast Neoplasms 331 Neoplasm Metastasis 243 Colorectal Neoplasms 214 Melanoma 213 Leukemia, Myeloid, Acute 191 Multiple Myeloma 180 Recurrence 169 Ovarian Neoplasms 169 Prostatic Neoplasms 163 Lymphoma, Non-Hodgkin 149 Lung Neoplasms 134 Pancreatic Neoplasms 125 Lymphoma 124 Carcinoma, Renal Cell 112 Leukemia, Lymphocytic, Chronic, B-Cell 111 Squamous Cell Carcinoma of Head and Neck 110 Stomach Neoplasms 92 Carcinoma, Hepatocellular 89 Lymphoma, Large B-Cell, Diffuse 88 Leukemia 88 Triple Negative Breast Neoplasms 86 Lymphoma, Follicular 82 Head and Neck Neoplasms 79 Glioblastoma 75 Myelodysplastic Syndromes 70 Urinary Bladder Neoplasms 68 Small Cell Lung Carcinoma 64 Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

ridaforolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Advanced Cancers × Clear all

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated

7 enrolled 13 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡